Murinized BCR-ABL+ B-lineage Acute Lymphoblastic Leukemia
Santana SanchezFarrar Lab8/21/19
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy
t(9;22) translocation
BCR-ABLUncontrolled Proliferation
Wikipedia
ABLBCR
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy• Peptides derived from BCR-ABL are antigenic
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy• Peptides derived from BCR-ABL are antigenic• Previous model: Arf-/- Pre-B cells express human BCR-ABL fusion protein
recapitulates BCR-ABL+ B-ALL in an immunocompetent mouse (LM138 cells)
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy
• Peptides derived from BCR-ABL are antigenic
• Previous model: Arf-/- Pre-B cells express human BCR-ABL fusion protein recapitulates BCR-ABL+ B-ALL in an immunocompetent mouse (LM138 cells)
• Manlove et al. 2016 showed that robust immunization with fusion peptide + checkpoint blockade led to significantly improved survival
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy
• Peptides derived from BCR-ABL are antigenic
• Previous model: Arf-/- Pre-B cells express human BCR-ABL fusion protein recapitulates BCR-ABL+ B-ALL in an immunocompetent mouse (LM138 cells)
• Manlove et al. 2016 showed that robust immunization with fusion peptide + checkpoint blockade led to significantly improved survival
• What is the problem?
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy
• Peptides derived from BCR-ABL are antigenic
• Previous model: Arf-/- Pre-B cells express human BCR-ABL fusion protein recapitulates BCR-ABL+ B-ALL in an immunocompetent mouse (LM138 cells)
• Manlove et al. 2016 showed that robust immunization with fusion peptide + checkpoint blockade led to significantly improved survival
• What is the problem?
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy• Peptides derived from BCR-ABL are antigenic• Previous model: Arf-/- Pre-B cells express human BCR-ABL fusion protein
recapitulates BCR-ABL+ B-ALL in an immunocompetent mouse (LM138 cells)• Manlove et al. 2016 showed that robust immunization with fusion peptide
+ checkpoint blockade led to significantly improved survival • Because of discrepancies between human and mouse BCR and ABL protein
sequence there are multiple foreign epitopes on the BCR-ABL fusion protein that are potentially driving the antileukemia immune response seen in Manlove et al.
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype• Recapitulate B-ALL in vivo
muBCR-ABL
Primary Bone Marrow Cells
Retroviral plasmid
Arf-/-
Cloning Strategy
muBCR-ABL geneblock 1 muBCR-ABL geneblock 2
NotI EcoRI
IRES Thy1.1
NotI EcoRI
Carrier Plasmid
Retrovirus
muBCR-ABL
~20 days
Primary Bone Marrow Cells
muBCR-ABL
Retroviral plasmid
Arf-/-Arf-/-
ST26
muBCR-ABL
~20 days
Characterize by Flow Cytometry
Characterize in vivo
In vitro studies
Primary Bone Marrow Cells
muBCR-ABL
Retroviral plasmid
Arf-/-Arf-/-
ST26
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype• Recapitulate B-ALL in vivo
ST26 Proliferation
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype• Recapitulate B-ALL in vivo
ST26 cells are sensitive to Abl kinase inhibitor Nilotinib
muBCR-ABL, ARF-/-(ST26)
huBCR-ABL, ARF-/-(LM138)
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype• Recapitulate B-ALL in vivo
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype
• B220+• BP1+• CD19+• IgM-
• Recapitulate B-ALL in vivo
HSC MLP NF B
PreBlate
PreBearlyCLP DJ-
ProBGL-ProB
FoB
AA4.1B220CD43CD24BP-1c-kitIL-7RCD19CD25IgM
Phenotypic Fraction: A B/C C’ D E F
Surf
ace
Prot
eins
Hardy 2004, B cell Protocols
B cell lineage
HSC MLP NF B
PreBlate
PreBearlyCLP DJ-
ProBGL-ProB
FoB
AA4.1B220CD43CD24BP-1c-kitIL-7RCD19CD25IgM
Phenotypic Fraction: A B/C C’ D E F
Surf
ace
Prot
eins
Hardy 2004, B cell Protocols
B cell lineage
WT
BM
ST26
D “Pre-B” 78.6E-F 18.4
D-F “Pre-B”E-F 3.67
D “Pre-B” 95.2
B220
IgM
B220
B220
CD43 IgM
D-F “Pre-B”
B220
CD43
C-D
CD25
BP1
A-C’ “Pro-B”
C-D
CD25
BP1
D-F “Pre-B”
B220
CD43
A-C’ “Pro-B”
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype
üB220+üBP1+üCD19+ü IgM-
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype• Recapitulate B-ALL in vivo
Conclusions
üGenerate muBCR-ABL+ B-ALL cell lineüProliferate independently in cultureüDependent on BCR-ABL tyrosine kinase activity üPre-B cell phenotype? Recapitulate B-ALL in vivo
Future Direction
• Survival analysis• Perform flow cytometry analysis on in vivo ST26 cells• Determine how ST26 cells respond to robust immunization +
checkpoint blockade therapy
Acknowledgements
Thank you to the Farrar Lab!Michael FarrarSean TracyCan HekimHrishi VenkateshRobin LeeLucy SjaastadDavid OwenLynn Heltemes HarrisGrey Hubbard
T35 Medical Student Summer Research ProgramDaniel L. Mueller
Stephanie Krischuk
Top Related